The efficacy and safety of dupilumab in Chinese patients with moderate‐to‐severe atopic dermatitis: a randomized, double‐blind, placebo‐controlled study

Author:

Zhao Y.1ORCID,Wu L.2,Lu Q.3,Gao X.4,Zhu X.5,Yao X.6ORCID,Li L.7ORCID,Li W.8ORCID,Ding Y.9,Song Z.10,Liu L.11,Dang N.12,Zhang C.13,Liu X.14,Gu J.15,Wang J.16,Geng S.17ORCID,Liu Q.18,Guo Y.19,Dong L.20,Su H.20,Bai L.20,O’Malley J.T.21,Luo J.22,Laws E.23,Mannent L.24,Ruddy M.25,Amin N.25,Bansal A.25ORCID,Ota T.25,Wang M.26,Zhang J.1ORCID

Affiliation:

1. Peking University People’s Hospital Beijing China

2. Hangzhou First People’s Hospital Hangzhou China

3. The Second Xiangya Hospital of Central South University Changsha China

4. The First Hospital of China Medical University Shenyang China

5. Wuxi Second People’s Hospital Jiangsu China

6. Hospital for Skin Diseases Institute of Dermatology Chinese Academy of Medical Sciences Nanjing China

7. Beijing Friendship Hospital Capital Medical University Beijing China

8. Huashan Hospital Fudan University Shanghai China

9. Shanghai Skin Disease Hospital Shanghai China

10. The Southwest Hospital of AMU Chongqing China

11. Peking University First Hospital Beijing China

12. Jinan Central Hospital Jinan China

13. Peking University Third Hospital Beijing China

14. University of Hong Kong‐Shenzhen Hospital Shenzhen China

15. Changhai Hospital of Shanghai Shanghai China

16. Ningbo No.2 Hospital Ningbo China

17. The Second Affiliated Hospital of Xi’an Jiaotong University Xi’an China

18. Tianjin Medical University General Hospital Tianjin China

19. Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine Shanghai China

20. Research & Development Sanofi Shanghai China

21. Research & Development Sanofi Cambridge MA USA

22. Research & Development Sanofi Indianapolis IL USA

23. Research & Development Sanofi Bridgewater MA USA

24. Research & Development Sanofi Paris France

25. Research & Development Regeneron New York NY USA

26. Medical, Sanofi China Shanghai China

Funder

Regeneron Pharmaceuticals

Sanofi

Publisher

Wiley

Subject

Dermatology

Cited by 36 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3